Walgreens to open more than 500 VillageMD primary care offices within stores

Walgreens to open more than 500 VillageMD primary care offices within stores
View As Webpage

Leverage data for better healthcare outcomes. >>
 
HIMSS
 
 

Thursday, July 9, 2020

 
 
Person drawing a picture of a robot

People perceive chatbot screeners as less capable than live responders, but value ability, trust in source above all

By Dave Muoio

Satisfaction with COVID-19 screening chatbots and adherence to the information they provide is primarily driven by the user's perception of the tool's ability, according to research recently published in the Journal of the American Medical Informatics Association.

Conducted by researchers from Indiana University and Temple University's respective business schools, the investigation asked participants to provide their reactions to fictional screening encounters between patients and either a human operator or a screening chatbot. In reality, the responses of each screener were identical.

"Our results show a slight negative bias against chatbots’ ability, perhaps due to recent press reports," the researchers wrote.

With this in mind, the researchers advised healthcare organizations employing the technology to be proactive in communicating the high-quality service their chatbot can provide.

"To offset users’ biases, a necessary component in deploying chatbots for COVID-19 screening is a strong messaging campaign that emphasizes the chatbot’s ability," they wrote. "Because trust in the provider strongly influences perceptions of ability, building on the organization’s reputation may also prove useful."

TOPLINE DATA

Across the study sample of 371 participants, chatbots were perceived to have less ability, integrity and benevolence than a human operator. However, this difference was often hand in hand or even secondary to participants' trust in the screening service's provider.

Perception of ability was primarily influenced by provider trust rather than responder type. Benevolence was dictated by responder type over provider trust, and integrity saw both as primary factors.

Perceived ability trumped responder type as the dominant factor when a handful of secondary measures, such as satisfaction or willingness to follow the screener's advice, were reviewed. Of note, the severity of the patient's condition did not have an impact on these secondary outcomes.

"When chatbots are perceived to provide the same service quality as human agents, users are more likely to see them as persuasive, be more satisfied, and be more likely to use them," the researchers wrote. "A user’s tech-savviness has only a small effect, so these results apply to both those with deep technology experience and those with little." 

HOW IT WAS DONE

In April, the researchers recruited and reviewed data from online participants tasked with viewing video vignettes of fictitious text chats between a COVID-19 screening hotline and a potentially symptomatic user. The researchers built these scenarios based on experiences with four COVID-19 chatbots and CDC-recommended screening questions, and designed different vignettes for a caller with mild or severe symptoms.

Participants watching each video were randomly informed that they would be viewing screening responses from either a human agent or a screening chatbot, despite no differences between the two in the vignette scripts. The participants then answered a series of questions on a seven-point scale to determine perceived ability, integrity, benevolence, persuasiveness, satisfaction, likelihood to follow advice, trust and willingness to use.

THE BACKGROUND

Chatbots were already seeing increased use across healthcare organizations to help coordinate care, deliver reminders or just generally lighten the load on human responders. And as COVID-19 cases mount in the U.S., more and more individuals have sought guidance on their symptoms from trusted sources.

"COVID-19 screening is an ideal application for chatbots because it is a well-structured process that involves asking patients a series of clearly-defined questions and determining a risk score," the researchers wrote.

"Chatbots can help call centers triage patients and advise them on the most appropriate actions to take, which may be to do nothing because the patient does not present symptoms that warrant immediate medical care. Despite all the potential benefits, like any other technology-enabled services, chatbots will help only if people use them and follow their advice."

NephU website screenshot

Otsuka rolls out new kidney focused resource platform NephU

By Laura Lovett

Pharma giant Otsuka is rolling out a new kidney focused platform called NephU that provides online resources about nephrology conditions and a place for clinicians to collaborate and share information amongst themselves, and with patients. 

Users will be able to tap into an online library of resources that include video, audio, webinars and podcasts. According to the site, the “community” includes a number of stakeholders, ranging from nephrologists, to dieticians and researchers, to administrators. The site has what it calls community corners, or sections targeted at a specific medical profession. For example, there is are corners for nurses, a pharmacist, payers, advanced practice providers and physicians. 

“We are excited to launch NephU as a value-added resource to the nephrology community. We plan to offer a wide range of information and resources in areas such as polycystic kidney disease (PKD) and other hereditary kidney diseases, general chronic kidney disease, anemia associated with Chronic Kidney Disease (CKD), renal replacement therapy options, and behavioral health for people living with kidney conditions,” Reza Moghadam, senior director, Field Medical Affairs, said in a statement. “Our goal is to expand and excite the conversation regarding best practices for kidney care and health. In the future, we plan to offer a microsite where patients and caregivers can directly access content.”

WHY IT MATTERS 

According to the CDC, 6 million adults in the U.S. have been diagnosed with kidney disease. In fact, in 2017 it was the ninth leading cause of death in the country. Diabetes, high blood pressure and a family history are factors that can put individuals at a higher risk for kidney disease.

THE LARGER TREND 

Otsuka has a long history of working in the kidney disease space. In 2018 it landed FDA clearance for the first treatment of autosomal dominant polycystic kidney disease (ADPKD).  

Otsuka has also been interested in digital adherence space for some time as well. It previously inked a five-year deal with digital health company Proteus, paying out $88 million towards the continued development and commercialization of an ingestible sensor-pill platform, as well as a wider investigation of digital medicines. In 2017 the companies won FDA clearance for a digital ingestion-tracking system, called Abilify MyCite, which is prescribed for treatment of schizophrenia, for acute treatment of manic and mixed episodes associated with bipolar disorder, and as an add on for depression.

But last January, following news of hardship at Proteus, Otsuka announced that it will be parting ways with the digital health company and pivoting from its current primary focus on mental health disorders towards cancers and infectious-disease treatments. The pharma giant acquired the full license to Proteus’ mental health treatment and adherence tech. Since then Proteus has filed for bankruptcy.

 

ADVERTISEMENT

The College of St. Scholastica

DIGITAL THERAPUTICS

Braingaze partners with Ping An, 7invensun to deliver ADHD diagnostic solutions in China

The three companies are now finishing the configuration of a comprehensive solution package that will allow Ping An Group to perform reliable, objective and convenient testing for ADHD patients.

 

DIGITAL THERAPUTICS

AliveCor adds ECG subscription service to its product line

KardiaCare provides users features that help interpret their heart data, monitor risk factors, identify symptom triggers and measure the impact of lifestyle changes.

 

FUNDING & IPOS

Kindbody's $32M Series B for women's health, K4Connect's $7.7M for senior tech and more digital health funding news

Also: Truepill to expand digital pharmacy business with $25 million Series B; Nucleai's precision oncology platform gains $6.5 million from Debiopharm.

 

OPERATIONS

Walgreens to open more than 500 VillageMD primary care offices within stores

The full service doctor's offices will be in 30 U.S. markets, with the intent to expand.

 

HIMSS TV

Sponsored: Helping businesses reopen safely during pandemic

Paladina Health's Sampath Narayanan and Salesforce's Chequeta Allen and Sean Kennedy discuss how Paladina Health, alongside Salesforce, is providing clients with a comprehensive return-to-work strategy.

 

HIMSS INSIGHTS

COVID-19 and Beyond

The latest issue in the HIMSS Insights series focuses on the implications of the coronavirus crisis for healthcare and healthcare digitization. Several months into the crisis at the time of publication, we try to identify major trends coming out of COVID-19 and unmet digital needs that are being unmasked. The second area of focus is digital health technology assessment which is arising in several healthcare systems and remains highly relevant during the pandemic and beyond.

 

ADVERTISEMENT

HIMSS Analytics
 

Real-time analytics, during the pandemic and beyond >>

PUTTING DATA TO WORK

This month, we look at the lasting lessons from the COVID-19 crisis about how data is exchanged, how it's managed, how it's visualized, how it's put to work informing patient care decisions and population health.

Facebook Twitter LinkedIn

MobiHealthNews & HIMSS Media.
Editorial Inquiries | Advertising | Privacy Policy | Unsubscribe

33 West Monroe Street, Suite 1700, Chicago, IL 60603-5616